The biotech boom of the past several years saw record-breaking IPO volume across the entire sector. Central nervous system (CNS) therapeutics companies received their fair share of attention, particularly in the peak biotech IPO years of 2014 and 2015.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?